<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03685084</url>
  </required_header>
  <id_info>
    <org_study_id>AT-101</org_study_id>
    <nct_id>NCT03685084</nct_id>
  </id_info>
  <brief_title>Investigation of AAI101 Safety, Tolerability &amp; PK in Healthy Volunteers</brief_title>
  <official_title>Phase I, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of AAI101 Administered Intravenously Alone or in Combination With Piperacillin or Cefepime to Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allecra</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allecra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To assess the safety and tolerability of single and multiple ascending intravenous doses
           of AAI101 (SAD &amp; MAD) in healthy male subjects.

        -  To assess the safety and tolerability of single and multiple ascending intravenous doses
           of AAI101 in combination with fixed intravenous doses of piperacillin or cefepime in
           healthy male subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2013</start_date>
  <completion_date type="Actual">January 13, 2014</completion_date>
  <primary_completion_date type="Actual">January 13, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Profile - Number of Subjects With at Least one Adverse Event</measure>
    <time_frame>Throughout the period that subjects receive study drug up to 5 days following discontinuation of study treatment</time_frame>
    <description>Safety will be evaluated from reported signs and symptoms and clinical laboratory tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AAI101 maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
    <description>Cmax will be compared before and after administration of AAI101 either alone or in the presence of cefepime or piperacillin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AAI101 Clast</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
    <description>Clast will be compared before and after administration of AAI101 either alone or in the presence of cefepime or piperacillin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AAI101 AUC(0-t) - AUC(0-8)</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
    <description>AAI101 Urea Under the Curve will be compared before and after administration of AAI101 either alone or in the presence of cefepime or piperacillin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AAI101 half life (t1/2)</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
    <description>AAI101 t1/2 plasma pharmacokinetic parameter will be compared for AAI101 alone or in the presence of cefepime or piperacillin</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>0.9% saline infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline 0.9% infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AAI101 i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg, 1g, 2g, 4g, 1g q6h, 2g q6h.
Drug-Drug Interaction:
Sequence 1 = piperacillin 4 g i.v. - AAI101 2 g i.v. - AAI101 2 g + piperacillin 4 g i.v. - cefepime 2 g i.v. - AAI101 2 g + cefepime 2 g i.v.
Sequence 2 = cefepime 2 g i.v. - piperacillin 4 g i.v. - AAI101 2 g + cefepime 2 g i.v. - AAI101 2 g i.v. - AAI101 2 g + piperacillin 4 g i.v.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Piperacillin i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Piperacillin 3 g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cefepime i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cefepime 1 g</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AAI101 i.v.</intervention_name>
    <description>600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)</description>
    <arm_group_label>0.9% saline infusion</arm_group_label>
    <arm_group_label>AAI101 i.v.</arm_group_label>
    <other_name>AAI101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline 0.9% infusion</intervention_name>
    <description>Vehicle infusion</description>
    <arm_group_label>0.9% saline infusion</arm_group_label>
    <arm_group_label>AAI101 i.v.</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin i.v.</intervention_name>
    <description>piperacillin 3 g i.v.</description>
    <arm_group_label>Piperacillin i.v.</arm_group_label>
    <other_name>Beta-lactam antibiotic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefepime i.v.</intervention_name>
    <description>cefepime 1 g i.v.</description>
    <arm_group_label>Cefepime i.v.</arm_group_label>
    <other_name>Beta-lactam antibiotic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male healthy volunteers aged between 18 and 45 years (inclusive) at screening.

          -  Body mass index (BMI) of 18.0 to 30.0 Kg/m2 (inclusive) at screening.

          -  Healthy as determined by the investigator on the basis of medical history, physical
             examination findings, clinical laboratory test results, vital sign measurements, and
             digital 12 lead ECG readings (all results were to be within normal range or considered
             non-clinically significant by the investigator).

          -  Non-smoker or smoker of fewer than 10 cigarettes per day as determined by medical
             history. Had to be able to abstain from smoking during the inpatient stay.

          -  Ability to communicate well with the investigator in the local language, and to
             understand and comply with the requirements of the study.

        Main Exclusion Criteria:

          -  Any significant cardiovascular (e.g., hypertension), hepatic, renal, respiratory
             (e.g., childhood asthma), gastrointestinal, endocrine (e.g., diabetes, dyslipidemia),
             immunologic, hematological, neurologic, or psychiatric disease.

          -  Acute disease state (e.g., nausea, vomiting, fever, diarrhea) within 7 days before
             study Day 1.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Healthy male subjects</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>September 25, 2018</last_update_submitted>
  <last_update_submitted_qc>September 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Cefepime</mesh_term>
    <mesh_term>Lactams</mesh_term>
    <mesh_term>beta-Lactams</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

